Shares of Celsion Co. (NASDAQ:CLSN) rose 15.4% during mid-day trading on Monday following a better than expected earnings announcement. The stock traded as high as $1.43 and last traded at $1.42, approximately 205,000 shares traded hands during mid-day trading. An increase of 55% from the average daily volume of 132,045 shares. The stock had previously closed at $1.23.
The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.05. Celsion had a negative net margin of 1,653.20% and a negative return on equity of 54.00%. The firm had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $0.13 million.
CLSN has been the subject of several recent analyst reports. Zacks Investment Research cut shares of Celsion from a “hold” rating to a “sell” rating in a research report on Wednesday, October 16th. ValuEngine upgraded shares of Celsion from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Brookline Capital Management restated a “buy” rating on shares of Celsion in a research report on Thursday, July 25th.
The company has a quick ratio of 3.47, a current ratio of 3.47 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $30.58 million, a price-to-earnings ratio of -2.09 and a beta of 1.93. The company’s 50-day moving average is $1.62 and its 200-day moving average is $1.80.
Celsion Company Profile (NASDAQ:CLSN)
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.
Recommended Story: How Do You Calculate Return on Equity (ROE)?
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.